2024-04-24 (三) 19:00 ~ 20:40

The effectiveness and safety of Pembrolizumab in patients with advanced
lung squamous cell carcinoma (SCC) have been extensively studied,
reflecting a significant advancement in oncological care. This speech explores
the experience, evidence, and excellence surrounding Pembrolizumab
therapy through case sharing.
Over the past years, Pembrolizumab has emerged as a cornerstone treatment
for advanced lung SCC, following its inclusion in the NCCN guideline prefer
regimen. With expanded reimbursement criteria, Pembrolizumab now offers
coverage for patients with a tumor proportion score (TPS) ranging from 0% to
100% in squamous lung cancer cases, potentially enhancing treatment
accessibility and efficacy.
Through case sharing, we highlight the real-world experiences of patients
receiving Pembrolizumab therapy. These cases provide valuable insights into
the effectiveness of Pembrolizumab in inducing tumor regression and
improving patient outcomes, thereby validating the evidence from pivotal
trials. Additionally, we address safety concerns associated with
Pembrolizumab treatment, underscoring the importance of vigilant monitoring
and management of immune-related adverse events.